U.S. Markets closed
  • S&P Futures

    4,317.75
    -23.75 (-0.55%)
     
  • Dow Futures

    33,836.00
    -219.00 (-0.64%)
     
  • Nasdaq Futures

    14,089.75
    -68.75 (-0.49%)
     
  • Russell 2000 Futures

    1,953.40
    -19.30 (-0.98%)
     
  • Crude Oil

    87.13
    -0.22 (-0.25%)
     
  • Gold

    1,817.50
    -12.20 (-0.67%)
     
  • Silver

    23.47
    -0.34 (-1.42%)
     
  • EUR/USD

    1.1236
    -0.0009 (-0.0787%)
     
  • 10-Yr Bond

    1.8480
    +0.0650 (+3.65%)
     
  • Vix

    31.96
    +0.80 (+2.57%)
     
  • GBP/USD

    1.3448
    -0.0015 (-0.1089%)
     
  • USD/JPY

    114.6700
    +0.0100 (+0.0087%)
     
  • BTC-USD

    36,872.65
    +216.56 (+0.59%)
     
  • CMC Crypto 200

    841.16
    -14.65 (-1.71%)
     
  • FTSE 100

    7,469.78
    +98.32 (+1.33%)
     
  • Nikkei 225

    26,964.26
    -47.07 (-0.17%)
     

Why Axsome Therapeutics Stock Took a Step Backwards This Week

·2 min read
Why Axsome Therapeutics Stock Took a Step Backwards This Week
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • AXSM

Shares of Axsome Therapeutics (NASDAQ: AXSM) lost 9.75% of their value through Thursday's closing bell this week, according to data from S&P Global Market Intelligence. The biotech's shares are currently well off of their 52-week highs due to a regulatory delay for its experimental major depressive disorder drug AXS-05. What's important to understand is that this regulatory hiccup reportedly centers around two issues with the company's analytical methods in the Chemistry, Manufacturing, and Controls section of the New Drug Application submitted to the Food and Drug Administration (FDA).